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Abstract
Endometriosis is a pseudoneoplastic disease that has a significant personal and social impact. Unlike other 
neoplastic diseases, its management is burdened by uncertainty and controversy. The aim of this article 
is to furnish clinicians with a simple, useful and updated tool to select an appropriate diagnostic-therapeutic 
care pathway for affected women. Guidelines and recommendations cite advances in diagnostics, novel 
medications and optimized assisted reproductive techniques; however, such advancements have not simplified 
the management of endometriosis, since they often lack an integrated, multidisciplinary view of diagnostic, 
therapeutic and reproductive scenarios that inevitably overlap in the management of the disease. We selected 
and compared major society guidelines on the diagnosis and treatment of endometriosis. Three international 
and 5 national guidelines were analyzed. The overlapping recommendations were extracted and mapped, 
developing a simplified diagnostic-therapeutic care pathway in the form of an algorithm. We subdivided 
the patient population attending our tertiary referral center according to 4 decision nodes: type (deep 
infiltrating endometriosis or isolated endometrioma); stage (I–IV according to the revised American Society 
for Reproductive Medicine classification); predominant health problem (pain or infertility); and fertility 
potential of the couple (normal/abnormal screening fertility). We identified 9 classes, each corresponding 
to a suggested mode of treatment (medical, surgical or assisted reproductive technique) according to the most 
recent evidence published. This simplified scheme is designed to standardize treatment and is intended for 
use as a tool in diagnostic and therapeutic planning with a view to reduce inappropriate treatment.
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Introduction
The care of patients with deep endometriosis requires 
treatment in a specialist referral center, where gynecolo-
gists collaborate in multidisciplinary teams and evaluate 
their work in a volume that is sufficient to maintain their 
high surgical skills. Such centers, designated in the litera-
ture as centers of excellence because they operate accord-
ing to principles of evidence-based medicine, provide for 
cooperation between gynecologist (group coordinator); 
pelvic sonographer and radiologist; gynecologist from 
the assisted reproductive technologies (ART) services; 
gyne cologic/colorectal/urologic laparoscopic surgeon; 
anesthetist for pain management; psychologist; profes-
sional nurse; and (ideally) a neurologist and a patient as-
sociation representative.1–3
The complex nature of such a system leaves it prone 
to error. Diagnostic Therapeutic Care Pathways (DTCP) 
were developed to improve reproducibility and unifor-
mity in the delivery of healthcare services and to minimize 
the occurrence of adverse events. They contextualize treat-
ment guidelines for a disease within the reality of a hos-
pital organization, while taking account of the resources 
available in order to achieve the best outcome (efficacy), 
with the best clinical practice (appropriateness), while op-
timizing resources and time (efficiency).
Endometriosis is estimated to affect 10% of women be-
tween the age of 20 and 40 years; about 20% of women are di-
agnosed with deep endometriosis. The social cost of the dis-
ease, in  terms of  illness and loss of  work productivity, 
is over $ 9,911 per patient per year.4 The reasons supporting 
the choice of disease for which a DTCP can be constructed 
rest on priority criteria: impact on the health of the indi-
vidual and the community; presence of specific guidelines; 
variability and unevenness in the delivery of services; and 
economic impact. Endometriosis meets these criteria and 
represents an ideal candidate for establishing a DTCP.
This paper aims to present a simplified algorithm we de-
veloped and adopted as DTCP in our tertiary referral cen-
ter for the management of patients with endometriosis. 
The scheme, based on published data and the latest major 
society international guidelines, may serve as a template 
for developing local care pathways.
Material and methods
A literature search was conducted for society guidelines 
for the clinical management of patients with endometriosis 
published in the last 5 years. Three international societies 
in the field of endometriosis, reproductive medicine and gy-
necology, and 5 national societies were included: the World 
Endometriosis Society (WES, 2017),5 the European Soci-
ety of Human Reproduction and Embryology (ESHRE, 
2014),6 the International Federation of Gynecology and 
Obstetrics (FIGO, 2016),7 the Society of Obstetricians and 
Gynaecologists of Canada (SOGC, 2010),8 the American 
College of Obstetricians and Gynecologists (ACOG, 2010),9 
the National Institute for Health and Care Excellence 
(NICE, 2017),1 the French College of Gynecologists and 
Obstetricians (CNGOF, 2018),10 and the Italian Society 
of Gynecology and Obstetrics (SIGO, 2018).11 The society 
recommendations were compared and presented system-
atically as an algorithm, along with the quality of evi-
dence6,8–11 and strength of recommendation.6,8,10,11
Results
Algorithm
The best way to illustrate a care pathway, essentially 
a series of decision nodes, is an algorithm, since it gives 
an  overview of  the  entire course of  decision-making. 
The algorithm (Fig. 1) shows how the clinician, following 
a course through 4 decision nodes (checkpoints), is able 
to subdivide the patient population into 9 classes (A–I), 
each requiring a specific care pathway. The diagnostic 
checkpoints and therapeutic classes are described below.
Diagnostic checkpoints
Check 1
On  the  basis of  findings from accurate history tak-
ing,1,6–8 self-report questionnaire (Endometriosis Health 
Profile EHP-30),12 rectovaginal exam,6,8 and transvaginal 
sonography,1,6,9,13 the gynecologist will be able to discrimi-
nate between peritoneal (superficial or deep) endometriosis 
and isolated endometrioma(s). A transvaginal sonogra-
phy exam should be performed by the coordinating gyne-
cologist and include consultation, according to standard 
protocol.14,15 Ovarian endometriomas are often markers 
of a more extensive disease.8 When the 2 ovaries adhere 
posteriorly to the uterus in the cavity of Douglas, they 
appear as “kissing ovaries” on the sonogram. This neces-
sitates ruling out deep pelvic endometriosis with bowel 
and tubal involvement (20% and 90%, respectively).16 When 
ovarian and deep endometriosis are present, the  latter 
is prioritized in the management pathway.
Check 1bis
When endometriosis has been found, the coordinat-
ing gynecologist stages the disease or orders further tests 
to stage it. If first-line investigations (history, consultation, 
transvaginal sonography) are inconclusive, second-line 
diag nostic tests should be ordered, e.g., pelvic magnetic 
resonance imaging (MRI) with contrast if organ involve-
ment is suspected (bowel, bladder, ureters).17 If bowel ste-
nosis is suspected, double-contrast barium enema and/or 
computed axial tomography (CT) of the colon, eventually 
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with virtual colonoscopy, can be ordered.1,8 Cystoscopy 
can be useful to rule out bladder trigone involvement.1,8 
If hydronephrosis is suspected, renal scintigraphy will yield 
useful information on residual renal function. Imaging 
with 16α-[18F]-fluoroestradiol positron-emission tomogra-
phy/CT has been shown useful in discriminating between 
scar tissue and endometriotic tissue in patients with a his-
tory of surgery and in the diagnosis of sites of extrapelvic 
disease. Its use is still limited to clinical studies, however.18
Check 2
Endometriosis causes pain and infertility. Pain manifests 
with dysmenorrhea in 80% of women and with dyspareunia 
in 30%. Between 30% and 50% of women will be affected 
by  infertility, defined as the  inability to conceive after 
1 year of regular, unprotected intercourse. The monthly 
pregnancy rate is 2–10% compared to the 15–20% rate for 
the healthy population.19 It is essential for the following de-
cision node to understand the main reason why the patient 
sought consultation (pain or infertility) in order to meet 
her health needs.1
Check 2bis
Most guidelines set an  endometrioma size of  3  cm 
as a cut-off value for clinical decision-making.6,8,14
Check 3
Since endometriosis affects women of reproductive age 
and ovarian surgery invariably leads to the depletion of oo-
cytes, the reproductive state of the woman and her partner 
should be evaluated. Fertility tests include the level of anti-
Müllerian hormone (AMH) in the blood, sonohysterosal-
pinography (SSG) and sperm test.10 Fertility screening (FS) 
comprises these tests. We will use the term “subfertile” 
to identify women who are infertile but with normal fertil-
ity screening test results.
Check 4
The  most widely used endometriosis classification 
is the revised American Society for Reproductive Medicine 
(r-ASRM) system issued in 1997 that uses 4 stages accord-
ing to local spread of the disease (I – minimal, II – mild, 
III – moderate, IV – severe).20 Other, more recent sys-
tems are the Enzian classification21 and the Endometriosis 
Fertility Index (EFI).22 All 3 have attracted criticism for 
the poor correlation between disease stage and symptoms 
and their inability to predict disease stage. Nonetheless, 
until new systems become available, it is recommended 
that patients undergoing surgery be evaluated according 
to the 4-stage r-ASRM classification and that those with 
deep endometriosis not yet treated surgically be evaluated 
according to the Enzian classification; finally, patients in 
whom fertility is a priority should be assessed according 
to the EFI.5
Therapeutic classes
Class A – patients with organ failure  
due to deep endometriosis
A1
In  cases of  deep endometriosis involving the  bowel, 
bladder or ureters, 3-month therapy with gonadotropin-
releasing hormone (GnRH) analogues can be considered 
before surgery.1,23
A2
Surgical treatment is indicated and necessary in cases 
of severe infiltrating or stenosing disease involving the 
bowel, bladder, ureters, or pelvic nerves.8
Class B – symptomatic patients  
with superficial or deep endometriosis
B1
Progestin or combined estrogen/progestin therapy can 
be considered as first-line treatment in patients with symp-
tomatic endometriosis since it has been demonstrated effec-
tive in relieving dysmenorrhea (decrease from 3 to 9 points 
out of 10 on the visual analogue scale (VAS)), dyspareunia 
and chronic pelvic pain in patients with disease involving 
the rectum, vagina and rectovaginal septum (RVS). There 
is no evidence for recommending therapy only to reduce 
lesion volume in order to prevent surgical complications.10
Since there is no significant difference in efficacy between 
hormone therapies, the choice should be based on safety 
parameters (e.g., risk of venous or arterial thrombosis), tol-
erability and costs. There is consensus on first prescrib-
ing progestins, then combined estrogen/progestin therapy 
as first-line therapeutic options. The GnRH agonist therapy 
or Danazol, though equally effective, should be considered 
second-line treatment owing to their side effects.11,24
Progestins can be administered via oral, intrauterine, 
intramuscular (IM) or subcutaneous (SC) route. The 2 
oral progestins most widely studied for their effect on deep 
endometriosis are norethindrone acetate (NETA) and 
dienogest. A  recent observational study showed that 
the two have a substantially similar benefit and that di-
enogest has better tolerability. The NETA has androgenic 
activity, is  partially metabolized into estrogen, which 
should protect against bone loss during prolonged therapy, 
and has greater progestin effects than dienogest,25 which 
has mainly antiandrogenic effects. Although the lowest 
dose approved by the U.S. Food and Drug Administra-
tion (FDA) for NETA is 5 mg daily, excellent results have 
been obtained with half the dose (2.5 mg daily). Dienogest 
can provide an effective long-term therapeutic option.26,27 
A daily dose of 2 mg was found to be significantly superior 
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to placebo and equally effective as GnRH agonists in re-
lieving pain.8,28 Desogestrel29 is another oral progestin that 
has been shown to reduce pain in patients with endome-
triosis of the RVS by 2 points on a VAS pain scale.10
Levonorgestrel-releasing intrauterine system (LNG-IUS) 
can be considered in patients with endometriosis of the RVS 
and adenomyosis, who no longer seek conception and do 
not tolerate systemic progestin administration.30 The lower 
amount of progestin released in the bloodstream through 
the IUD reduces the risk of systemic side effects.
Depot medroxyprogesterone acetate (DMPA), IM or SC 
formulation is poorly manageable because its action can 
persist for more than 3 months after IM injection and 
the lack of androgenic properties increases the risk of bone 
mineral density loss and hypokalemia during prolonged 
use. Estrogen/progestins can be administered by oral, vagi-
nal or transdermal route with equal efficacy.1,4,17,24
Preparations with a lower percentage of ethinylestra-
diol and containing second-generation progestins should 
be preferred. They can be administered cyclically or con-
tinuously. Continuous administration is preferable when 
the prevalent symptom is dysmenorrhea.
The GnRH agonists relieve endometriosis-related pain, 
although there is limited evidence regarding dosage and 
duration of treatment31 (strength of recommendation A).6 
A GnRH agonist should never be used for prolonged pe-
riods without the addition of estrogen therapy (e.g., 1 mg 
of 17-alpha estradiol or equivalent).8,9 The GnRH agonists 
do not cause flare-ups, have a rapid effect and suppress the 
 pituitary gland in a dose-dependent manner. The FDA has 
recently approved their use (Elagolix) for the treatment 
of moderate-to-severe pain (dose 150 mg daily or 200 mg 
twice daily).32
In women with endometriosis of  the RVS refractory 
to medical or surgical treatment, aromatase inhibitors 
with combined estrogen/progestin therapy or progestin 
therapy alone or with GnRH analogues can be considered 
as they have been shown to reduce endometriosis-related 
pain33 (strength of recommendation B).6
B2
Between 1/4 and 1/3 of patients do not respond to medical 
therapy, probably because of progesterone resistance.34,35 
Surgical treatment of endometriosis is indicated in patients 
with pelvic pain who do not respond to, decline or have 
contraindications to medical therapy in order to relieve 
endometriosis-related pain and improve the patient’s qual-
ity of life (evidence level IIIA)6,9 (strength of recommenda-
tion B).8
The goal of conservative surgery is  to remove endo-
metriotic lesions, restore normal anatomy, and preserve 
visceral innervation and fertility.8,11,36 Shaving, discoid 
and segmental resection are the most used techniques 
in the surgical management of intestinal endometriosis.37 
There is evidence for the superiority of the laparoscopic 
over the laparotomic approach in the treatment of pelvic 
endometriosis, independent of disease severity, as  long 
as surgery is performed in a referral center highly special-
ized in endoscopic pelvic surgery and by surgeons expert 
in treatment of the disease11 (evidence level IIIA).8 Non-
conservative surgical treatment (hysterectomy and adnex-
ectomy) is reserved for cases with pain refractory to medi-
cal and surgical therapy and in women in perimenopause 
who do not desire future pregnancies. In such cases, visible 
endometriosis must be completely removed.1,6,11
B3
After excisional surgery, hormone therapy should be 
considered to prolong the benefits obtained with surgery 
and to prevent disease recurrence38 (evidence level A).6
Class C – subfertile patients  
with early stage endometriosis
C1
Because adequate evidence is lacking in subfertile women 
with endometriosis, we recommend against prescribing 
hormone therapy before any intervention to improve spon-
taneous pregnancy rates. The only benefit of prescription 
is pain relief (strength of recommendation, good practice 
point (GPP)).6
C2
In subfertile women with r-ASRM stage I/II endome-
triosis, ablative or excision laparoscopy of endometriotic 
lesions raises the pregnancy rate as compared to diag-
nostic laparoscopy alone39,40 (evidence level I)8 (strength 
of recommendation A).6 Eight patients need to be treat-
ed to achieve pregnancy in 1 of them. It would be more 
sensible to propose surgical treatment in young patients 
(<37 years) with a brief duration of infertility (<4 years), 
presence of ovulatory cycles, normal uterine anatomy, and 
partner’s normal sperm function.8
C3
If spontaneous conception does not occur within 6 months 
after surgery, ART should be advised.11 In infertile women 
with r-ASRM stage I/II endometriosis, it  is  reasonable 
to propose within 6 months after surgery a cycle of ovar-
ian stimulation followed by intrauterine insemination (IUI) 
rather than further expectant management.41 The pregnan-
cy rate in such cases is similar to that reported for infertility 
of unknown origin42 (strength of recommendation C).6
Class D – subfertile patients with advanced stage 
endometriosis and infertile patients  
with endometriosis
In subfertile women with r-ASRM stage III/IV endome-
triosis, there are no controlled studies comparing reproduc-
tive outcome after surgery and after expectant manage-
ment. Prospective cohort studies showed a higher crude 
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spontaneous pregnancy rate after laparoscopic surgery 
than after expectant management.43,44 However, the benefit 
of reproductive outcome obtained from surgical eradica-
tion of deep endometriosis compared to expectant man-
agement before ART has not yet been clearly established 
(strength of recommendation C).6 The literature contains 
no randomized studies; there are only 2 prospective cohort 
studies that showed conflicting results. While some data 
suggests that surgical resection of endometriosis can im-
prove the pregnancy rate, ovarian damage with decrease 
in the number of antral follicles can occur after the pro-
cedure.45,46 The pregnancy rate after ART in women with 
deep endometriosis is the same as that after ART for other 
indications47 (strength of recommendation C).6 An im-
proved outcome of ART after GnRH analogue therapy for 
3–6 months before ART was mentioned in a single report 
and not confirmed to date.23 Currently, there is weak evi-
dence for the utility of this therapy (strength of recom-
mendation B).6
Class E – symptomatic patients  
with endometrioma size >3 cm and normal FS
E1
Preoperative medical therapy should be understood 
as symptomatic and not cytoreductive since the lesions 
do not regress completely48 and resume their metabolic 
activity when therapy is stopped.11,49 Nonetheless, a recent 
study reported a marked reduction in cyst dimension after 
dienogest therapy.26
E2
It is reasonable to propose enucleation of endometrio-
mas >3 cm in symptomatic women6 with intact ovarian 
reserve, large unilateral cysts, or radiologically or clini-
cally suspected cysts.34 Compared with vaporization 
or coagulation of the cyst bed, excision of endometriotic 
cysts is better for reducing the number of recurrences, and 
the persistence/onset of pelvic pain.9 It is also associated 
with a higher rate of spontaneous pregnancy in the short 
and long term50,51 (evidence level I)8 (strength of recom-
mendation A and B).6
E3
In patients who do not desire future pregnancies, post-
operative hormone therapy can be proposed, since it has 
demonstrated a lower recurrence rate (evidence level IA),8 
independent of the type of progestin used.11
Class F – symptomatic patients  
with endometrioma size >3 cm  
and abnormal fertility tests
Laparoscopic stripping is associated with a reduction 
in ovarian reserve, which is quantifiable with a mean post-
operative decrease in AMH of 1.13 ng/mL.52,53 Patients with 
endometrioma had significantly lower AMH levels than 
age-matched patients with no endometrioma, irrespective 
of the type of surgery, and reduced response to ovarian 
stimulation in the presence of large cysts.34 Patients with 
symptomatic ovarian endometriosis, especially if bilateral, 
should be adequately counseled on the risks of reduced 
ovarian function or premature ovarian failure. The risks 
of surgery should be weighed against the benefits in women 
with a history of ovarian surgery6 or low AMH levels (near 
1 ng/mL). An option in selected cases is preservation of fer-
tility via cryopreservation of ovarian cortical fragments 
or mature oocytes obtained with superovulatory induction 
and transvaginal ultrasound-guided oocyte retrieval.11,55 
Alcohol sclerosing therapy is  an  technique alternative 
to laparoscopic enucleation and may be considered in such 
circumstances, though it has not been tested in adequately 
sized patient samples in randomized prospective trials.10
Class G – symptomatic patients  
with endometrioma size <3 cm
In cases of endometrioma size <3 cm, watchful wait-
ing and medical therapy for pain relief are recommended 
(evidence level IA).8
Class H – subfertile patients with endometrioma
Young women with regular menstrual cycles in whom 
endometrioma is incidentally discovered, without signs 
of malignancy, and with good ovarian reserve should be 
encouraged to conceive naturally for a  limited amount 
of time.34 If, however, natural conception fails and a course 
of ART is planned, excisional surgery can be considered 
to improve follicular access.6,8
Class I – infertile patients with endometrioma
In  infertile patients with endometrioma size >3 cm, 
there is no evidence that cystectomy before ART improves 
the pregnancy rate42,56 (strength of recommendation A).6 
The results of ART are similar for women with and those 
without endometrioma, even if the number of oocytes re-
trieved is smaller, indicating a reduced ovarian reserve.11,57
Atypical endometriomas or  cysts with suspicious 
appear ance absent, and asymptomatic women of advanced 
reproductive age with reduced ovarian reserve, bilateral 
endometriomas or a history of ovarian surgery may ben-
efit from direct access to ART since surgery may further 
compromise ovarian function and delay the start of treat-
ment.34 Improved outcome after ART following GnRH 
analogue therapy for 3–6 months before starting ART 
therapy was reported in 1 study and never replicated23; 
further findings are awaited. Currently, there is weak evi-
dence for the utility of this therapy (strength of recom-
mendation B).6 Outcome after ART is poorer for women 
with concomitant deep endometriosis.58
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Discussion
Due to  the  poor correlation with disease symptoms 
as  well as  a  lack of  predictive prognosis and unclear 
pathways of treating pelvic pain and infertility, the cur-
rent classification systems for endometriosis, which are 
based on disease extension, continue to attract criticism. 
Adamson stated that a good classification system is one 
that provides a simple description of the disease, correlates 
well with the pain and infertility experienced by women, 
and predicts response to pain relief, infertility and recur-
rence of post-treatment symptoms.59
As the primary goal is treating the patient rather than 
the disease, we developed a patient-based classification 
system concerning patients’ health needs, identifying them 
as possible determinants of therapeutic choices. Personal-
ized medicine emphasizes the customization of health-
care, where decisions and practices are tailored to indi-
vidual patients whenever possible to improve tolerability 
and compliance.60 However, unless details are provided 
on the parameters that lead to personalized choices, a ge-
neric appeal to personalized therapy risks turning into 
a  justification for empiricism. Indeed, in clinical prac-
tice, physicians are more comfortable with pursuing these 
goals if pragmatic aids, such as predefined algorithms, 
are provided. Therefore, it  is advisable to set up a clear 
decision-making process for complex situations in a com-
plex environment.
In  medicine, algorithm-based practice implies that 
the sequence is strictly followed and that the physician 
does not base primary decisions on  individual patient 
characteristics. Conversely, a patient-tailored approach 
adopts a treatment strategy based on the individual pa-
tient’s specific disease situation. Our algorithm was set 
up in  an  attempt to  merge patient-related parameters 
(pain, pregnancy desire and fertility status) with disease-
related parameters (superficial or deep endometriosis vs 
isolated endometrioma, disease staging), bearing in mind 
that a patient-tailored approach and an algorithm-based 
decision-making are not mutually exclusive but rather 
complementary.
For planning and analyzing the  feasibility of  DTCP 
in a referral center, the subdivision in patient groups is cru-
cial to help clinicians to determine their own adherence 
to the management pathway and to monitor the quality 
of care through patient’s outcomes. For instance, on the ba-
sis of the current literature on women with endometrio-
sis, population A should be expected not to exceed 5% 
of the total37; population B2 to be about 25% of popula-
tion B135; ans populations C3, D and H/I to have pregnancy 
rates ≥35%, ≥30% and ≥30%, respectively.57,60
Though established in gynecological oncology, DTCP 
have not yet become part of clinical practice in the man-
agement of benign gynecological conditions. The algo-
rithm presented in this article has the potential to help 
the clinician reduce interindividual variability and ensure 
patient-tailored treatment. We are confident that the dis-
semination and adoption of this management tool may, 
through consistent implementation, lead to the standard-
ization of care.
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